These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 17629666)
1. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666 [TBL] [Abstract][Full Text] [Related]
2. Rapid switching between transdermal fentanyl and methadone in cancer patients. Mercadante S; Ferrera P; Villari P; Casuccio A J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965 [TBL] [Abstract][Full Text] [Related]
3. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
4. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851 [TBL] [Abstract][Full Text] [Related]
5. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307 [TBL] [Abstract][Full Text] [Related]
7. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
9. Management of cancer-related pain with transdermal fentanyl. Leelanuntakit S J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606 [TBL] [Abstract][Full Text] [Related]
10. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716 [TBL] [Abstract][Full Text] [Related]
11. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884 [TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185 [TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
14. Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161 [TBL] [Abstract][Full Text] [Related]
15. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain. Lorvidhaya V; Katanyoo K; Srisomboon J; Suprapaphorn P; Cheewakriangkrai C J Med Assoc Thai; 2004 Mar; 87(3):319-25. PubMed ID: 15117050 [TBL] [Abstract][Full Text] [Related]
17. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298 [TBL] [Abstract][Full Text] [Related]
18. [Transdermal route as an alternative to oral administration of opioids in cancer pain]. Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889 [TBL] [Abstract][Full Text] [Related]
19. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl]. Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768 [TBL] [Abstract][Full Text] [Related]
20. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Otis J; Rothman M Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]